TSTickerStarGet alerts

CALC 10-Q filed 2026-11-10 | Key takeaways

CALC filed its 10-Q; the most relevant disclosure change is expanded Going concern: Management states that based on current operating plans, cash, cash equivalents and short-term investments of $13.8 million may not be sufficient to fund operations for a period of one year following issuance of financial statements, raising substantial doubt.

Share this story

Key takeaways

  • Going concern: Management states cash, cash equivalents and short-term investments of $13.8 million may not be sufficient to fund operations for one year following issuance of financial statements.

  • Reverse stock split: A 1-for-5 reverse stock split became effective August 28, 2026, reducing common stock outstanding from approximately 34 million pre-split shares to 6.9 million post-split shares.

  • PIPE financing: The company raised approximately $15 million in gross proceeds through a June 2026 private placement, issuing 3.7 million units at $4.0165 per unit.

  • Loan amendment: The June 2026 first amendment to the loan agreement extended the interest-only period by one year to September 2027 and extended maturity to September 2029.

  • Fair value gains: Non-cash gains from fair value adjustments on warrant liability and promissory note contributed $3.3 million to Q3 2026 other income, compared to a $2.0 million loss in Q3 2025.

  • Research and development: R&D expenses decreased 40% year-over-year to $2.3 million in Q3 2026, reflecting the pause in the KOURAGE AKI trial and reduced clinical activity.

  • Warrant liability: The warrant liability decreased significantly from $8.0 million at December 31, 2025 to $0.3 million at September 30, 2026, due to fair value adjustments and Series A warrant expiration.

Key metrics

Net loss (Q3)three months ended September 30, 2026
$1.674 milliondown from $7.804 million
Net loss (9M)nine months ended September 30, 2026
$4.350 milliondown from $18.802 million
Cash and cash equivalentsSeptember 30, 2026
$4.574 milliondown from $11.520 million at December 31, 2025
Short-term investmentsSeptember 30, 2026
$9.194 millionup from $1.496 million at December 31, 2025
Research and development (Q3)three months ended September 30, 2026
$2.319 milliondown from $3.851 million
General and administrative (Q3)three months ended September 30, 2026
$2.432 millionup from $1.767 million
Change in fair value of financial instruments (Q3)three months ended September 30, 2026
$3.300 million gaincompared to $2.000 million loss in Q3 2025
Net loss per share (Q3)three months ended September 30, 2026
$(0.24)$(2.59) in Q3 2025

Disclosure changes

  • Going concern

    Management states that based on current operating plans, cash, cash equivalents and short-term investments of $13.8 million may not be sufficient to fund operations for a period of one year following issuance of financial statements, raising substantial doubt about the company's ability to continue as a going concern. The company expects to fund its current operating plan only into the second half of 2027.

    The going concern risk has been continuously disclosed and is material to investment decisions as the company will need substantial additional capital to complete development and commercialization of product candidates.
  • Reverse stock split

    A 1-for-5 reverse stock split was approved by stockholders on August 19, 2026 and became effective August 28, 2026. Authorized shares were reduced from 500,000,000 to 100,000,000. All share and per share amounts have been retroactively restated.

    The reverse stock split reduced shares outstanding from approximately 34 million pre-split to 6.9 million post-split and may affect per-share metrics and market price.
  • Warrant liability

    Warrant liability decreased to $0.3 million at September 30, 2026, down from $8.0 million at December 31, 2025, primarily due to fair value adjustments (net decrease of $7.7 million during nine months ended September 30, 2026) and expiration of Tranche A Warrants.

    The significant reduction in warrant liability represents non-cash gains that positively impacted net income but does not reflect actual cash proceeds or improvement in fundamental business performance.
  • PIPE financing

    On June 25, 2026, the company completed a PIPE financing raising approximately $15 million in gross proceeds through issuance of 3.7 million units at $4.0165 per unit. Each unit consisted of common stock (or pre-funded warrant) plus rights to receive Series A and B warrants upon stockholder approval.

    The $15 million PIPE financing was a significant capital raise that extended the company's cash runway but resulted in dilution to existing shareholders.
  • Short-term investments

    Short-term investments increased to $9.2 million at September 30, 2026, up from $1.5 million at December 31, 2025, now including U.S. Treasury bills ($4.2 million) and corporate debt securities ($0.5 million) in addition to commercial paper and government-sponsored mortgage-backed securities.

    The shift from cash to short-term investments represents a change in liquidity management, with the company holding more fixed-income securities.
  • Accrued expenses

    Accrued expenses increased to $1.6 million at September 30, 2026, up from $0.3 million at December 31, 2025, primarily due to $0.6 million in accrued payroll and employee benefits, $0.5 million in accrued professional fees, and $0.2 million in accrued severance.

    The increase in accrued expenses, particularly severance, may indicate workforce reductions or restructuring activities.

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow CALC in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert